Filing Flows › Comparisons › ICCC vs AWHL
Immucell vs Aspira Women's Health: ICCC and AWHL compared
Immucell is the larger company: $7.2M of revenue in its latest quarter (Q2 2026) against $2.0M for Aspira Women's Health (Q2 2026). Immucell is growing faster (+12% against -15% a year earlier). Immucell is more profitable, with an operating margin of 26.9% against -89.7%.
Where the money goes: ICCC and AWHL
Immucell (ICCC) · Q2 2026
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
Aspira Women's Health (AWHL) · Q2 2026
Aspira Women's Health, Q2 2026: revenue $2.0M (-15% year over year), operating margin -89.7%, net loss $2.4M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Immucell (ICCC) | Aspira Women's Health (AWHL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $7.2M | $2.0M |
| Revenue growth, Y/Y | +12% | -15% |
| Gross margin | 33.9% | — |
| Operating margin | 26.9% | -89.7% |
| Net earnings | $1.8M | −$2.4M |
| Net margin | 25.5% | -118.3% |
| Operating cash flow | $3.0M | −$2.0M |
| Free cash flow | $2.3M | — |
Questions
Which is bigger, Immucell or Aspira Women's Health?
Immucell is the larger company: $7.2M of revenue in its latest quarter (Q2 2026) against $2.0M for Aspira Women's Health (Q2 2026).
Is Immucell or Aspira Women's Health growing faster?
Immucell is growing faster (+12% against -15% a year earlier).
Which is more profitable, Immucell or Aspira Women's Health?
Immucell is more profitable, with an operating margin of 26.9% against -89.7%.
More: Immucell earnings · how Immucell makes money · Aspira Women's Health earnings · how Aspira Women's Health makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.